According to previously published data, PD patients harboring PRKN mutations require a low LEDD for excellent control of motor signs, but despite receiving markedly low doses of levodopa, they exhibited the frequent development of motor complications and dyskinesias from early disease stages. Here, PRKN is linked to drug-induced dyskinesia.